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Abstract
Background: Studies have demonstrated that the use of implantable cardioverter defibrillators
(ICDs) is effective for the primary prevention of arrhythmic events but due to imposing costs, there
remains a need to identify which patients will derive the greatest benefit. Microvolt T-wave
alternans (MTWA) has been proposed to assist in this stratification.
Methods: We systematically searched the literature using MEDLINE, EMBASE, Current Contents,
the Cochrane Library, INAHTA, and the Web of Science to identify all primary prevention
randomized controlled trials and prospective cohort studies with at least 12 months of follow-up
examining MTWA as a predictor of mortality and severe arrhythmic events in patients with severe
left-ventricular dysfunction. The search was limited to full-text English publications between January
1990 and May 2007. The primary outcome was a composite of mortality and severe arrhythmias.
Data were synthesized using Bayesian hierarchical models.
Results: We identified no trials and 8 published cohort studies involving a total of 1,946 patients,
including 332 positive, 656 negative, 84 indeterminate, and 874 non-negative (which includes both
positive and indeterminate tests) MTWA test results. The risk of mortality or severe arrhythmic
events was higher in patients with a positive MTWA compared to a negative test (RR = 2.7, 95%
credible interval (CrI) = 1.4, 6.1). Similar results were obtained when comparing non-negative
MTWA to a negative test.
Conclusion:  A positive MTWA test predicts mortality or severe arrhythmic events in a
population of individuals with severe left ventricular dysfunction. However, the wide credible
interval suggests the clinical utility of this test remains incompletely defined, ranging from very
modest to substantial. Additional high quality studies are required to better refine the role of
MTWA in the decision making process for ICD implantation.
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Background
Implantable cardioverter defibrillators (ICDs) decrease
mortality principally by detecting and treating tachyar-
rhythmias, the most common cause of sudden cardiac
death (SCD)[1]. Although ICDs were originally used for
secondary prevention among survivors of cardiac arrest or
malignant arrhythmias, they have also been effective for
primary prevention in high-risk patients without a history
of malignant arrhythmias or SCD [2,3]. Consequently,
prophylactic ICD therapy has been recommended for
patients with reduced ejection fractions, resulting in a
large number of potentially eligible patients [2,4,5]. Due
to the substantial costs, as well as potential physical and
psychological adverse effects, there is a need for better
patient selection [6]. Novel diagnostic tests may have a
role in improving risk stratification for ICD implantation
[4].
Microvolt T-wave alternans (MTWA) represents a promis-
ing candidate test to stratify the risk among a primary pre-
vention population [7,8]. MTWA, which usually involves
an exercise treadmill test, is non-invasive and relatively
inexpensive. Some studies have suggested that patients
with negative MTWA tests have an extremely low risk for
SCD or cardiac arrest [7] but conflicting opinions exists
[9-12]. We therefore undertook a systematic review and
meta-analysis to determine the utility of MTWA for risk
stratification for primary prevention of patients with
severe left ventricular dysfunction. Our objectives were to
systematically review the existing medical literature and
quantitatively summarize the utility of MTWA in perform-
ing primary prevention risk stratification.
Methods
Search Criteria
We performed a systematic literature search for all rand-
omized controlled trials and prospective cohort studies
published in English between January 1990, 4 years
before the publication of the first clinical application of
MTWA [13], and May 2007. Using the terms "MTWA" or
"T wave alternans", we searched the following databases:
MEDLINE, EMBASE, Current Contents, and the Web of
Science, restricting our search to full text articles involving
human subjects. We also hand-searched The Cochrane
Library, INAHTA, and references of relevant articles,
reviews, and previous meta-analyses for additional stud-
ies. Since only observational studies were identified, all
elements of this meta-analysis strictly followed the guide-
lines described in the Meta-analysis of Observational
Studies in Epidemiology (MOOSE) proposal [14].
Inclusion Criteria
We downloaded all identified articles to Reference Man-
ager (Version 11), and study eligibility was assessed first
by examining titles and abstracts (CJA). We restricted our
meta-analysis to studies examining MTWA in primary pre-
vention. We excluded studies with patient populations
involving a history of (resuscitated) cardiac death or
malignant arrhythmias, Brugada Syndrome, or Long QT
Syndrome. The inclusion criteria were: 1) original full
length research article; 2) randomized controlled trial or
prospective cohort study design; 3) exercise-induced
application of MTWA; 4) human participants with left-
ventricular dysfunction and no history of previous
arrhythmic event; 5) reported meaningful clinical end-
points including all-cause mortality (ACM), SCD, severe
arrhythmias, ventricular tachycardia (VT), ventricular
fibrillation (VF), or ICD shock as a function of MTWA
results. We contacted study authors to resolve important
ambiguities (n = 2). Duplicate publications, studies with
a follow-up of less than 12 months, and studies in
patients without severe left ventricular dysfunction (due
to their underlying low arrhythmic risk and fundamental
differences from patients with established cardiovascular
disease) were excluded. We defined patients with severe
left ventricular dysfunction as those with an ejection frac-
tion of ≤ 35%.
Data Extraction
Two investigators (CJA and KBF) independently extracted
data using a structured and pilot-tested extraction form,
with discrepancies resolved by consensus. Abstracted data
included: study design, study funding, inclusion and
exclusion criteria, details regarding MTWA testing and
classification of results, baseline demographic and clinical
characteristics of participants, duration of follow-up, end-
points evaluated, multivariable analyses, and main con-
clusions.
We assessed study quality with a modified 7-item list
based on QUADAS [15], a quality assessment tool used
for diagnostic accuracy studies [see Additional file 1]. We
could not use QUADAS directly as no standard reference
test was available. Briefly, studies received one point for
each item they reported, for a maximum score of 7. We
then classified studies as having good (≥ 6), moderate (≤
4 and < 6), or poor (< 4) quality. This quality assessment
was not used to assess study inclusion or exclusion, but
was included as a study characteristic.
Statistical Analyses
Our primary analysis examined MTWA as a predictor of a
composite of mortality or severe arrhythmic events in pri-
mary prevention of patients with severe left-ventricular
dysfunction. In secondary analyses, we examined the use
of MTWA uniquely as a predictor of mortality (all-cause
mortality, cardiac death, and/or arrhythmic death). For
each study, we determined: the percentage of patients
tested as positive, negative, or indeterminate, and the per-
centage of patients who had the endpoint in each of theseBMC Cardiovascular Disorders 2009, 9:5 http://www.biomedcentral.com/1471-2261/9/5
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MTWA categories. Since some studies did not report out-
comes for patients in the indeterminate category, the sen-
sitivity and specificity reported in these studies are not
valid measures. In studies with available data, we re-calcu-
lated sensitivity, specificity, and positive and negative pre-
dictive values by comparing non-negative and negative
MTWA. For each MTWA category, we calculated the prob-
ability of the outcome given a positive test result (positive
predictive value) and the probability of the absence of the
outcome given a negative test result (negative predictive
value). Given the variability in disease prevalence and
duration across studies and the effect of these variables on
predictive values, we decided that only the ratios compar-
ing predictive values between categories (i.e., the relative
risk) could reasonably be pooled across studies [16].
We carried out separate meta-analyses comparing each
pair of MTWA categories in terms of risk ratios for each
endpoint. We used a Bayesian hierarchical model with
non-informative prior distributions to estimate the over-
all risk ratios using the WinBUGS software package [17].
We reported the posterior median and 95% credible inter-
vals (CrI) for the parameters of interest. All plots were
made using the R software package.
We also carried out two sensitivity analyses. In the first, we
examined the effect of follow-up time by restricting our
analysis to studies with between 1 and 2 years of follow-
up. In the second, we excluded studies that included ICD
shocks as part of their composite endpoint.
Results
Study and Participant Characteristics
No randomized controlled trials examining MTWA in pri-
mary prevention were identified. We identified 8 prospec-
tive cohort studies involving a total of 1,946 participants
(Figure 1) [6,18-24]. All studies were identified in
Flow diagram of systematic literature search, study selection, and reasons for exclusion Figure 1
Flow diagram of systematic literature search, study selection, and reasons for exclusion.BMC Cardiovascular Disorders 2009, 9:5 http://www.biomedcentral.com/1471-2261/9/5
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MEDLINE, although some were also found in other data-
bases.
The characteristics of included studies are presented in
Table 1. The underlying cardiac pathology varied between
studies but the age and sex distributions were relatively
similar. Studies also varied in sample size and duration of
follow-up. Four studies were classified as being of good
quality [6,18,19,22], and 4 were of moderate quality
[20,21,23,24].
Differences existed in the categorization schemes of
MTWA test results and in the percentage of patients in the
different MTWA categories (Table 2). Of the 1,946
patients, 332 had a positive MTWA test, 656 had a nega-
tive test, 84 had an indeterminate test, and 874 were clas-
sified as non-negative. Three studies excluded
indeterminate patients, preventing the calculation of valid
measures of sensitivity, specificity, and positive and nega-
tive predictive values. In the remaining 5 studies, MTWA
sensitivity and negative predictive values were high (Table
2). However, MTWA specificity and positive predictive
values were relatively modest.
Results of the Meta-Analyses
In our primary analysis of the composite endpoint of
mortality and severe arrhythmia, we pooled data across
studies to investigate the predictive ability of MTWA (Fig-
ures 2 and 3). Different numbers of studies were used in
each meta-analysis, reflecting the variability in reporting
of  outcomes as a function of MTWA categories. The risk
of mortality or severe arrhythmic events with positive
MTWA was increased compared to negative test results
(RR = 2.7, 95%CrI = 1.4, 6.1) (Figure 2). Similar results
were obtained when comparing non-negative to negative
MTWA (RR = 2.6, 95%CrI = 1.4, 5.8) (Figure 3). There
were insufficient data to make any statements regarding
the predictive utility of the indeterminate group (positive
vs indeterminate: RR = 1.1, 95%CrI = 0.4, 3.9; indetermi-
nate vs negative: 2.5, 95%CrI = 0.8, 5.4). In secondary
analyses, we examined MTWA as a predictor of mortality.
However, with only 3 studies [18,21,24] reporting all-
cause mortality, cardiac death, or arrhythmic death, this
analysis provided inconclusive results (positive vs nega-
tive: RR = 1.94, 95%CrI = 0.6, 10.3; non-negative vs nega-
tive: RR = 1.94, 95%CrI = 0.4, 11.8).
We also conducted two sensitivity analyses. In the first, we
restricted our analysis to the 7 studies that had follow-up
durations between 1 and 2 years. In this analysis, we
found that patients with a non-negative MTWA had three-
times the risk of experiencing an arrhythmic event or
death in the 1–2 years following MTWA testing than
patients with a negative MTWA result (RR = 3.1; 95%CrI =
1.3, 9.5). These results are consistent with those obtained
in our primary analysis. In the second, we excluded the
study by Bloomfield and colleagues [6], which included
ICD shocks as part of their composite endpoint. The
inclusion of this trial appears to have had a minimal effect
on our estimates (non-negative vs negative without
Bloomfield: RR = 2.2, 95% CI = 1.2, 5.5).
Table 1: Characteristics of prospective cohort studies examining microvolt T-wave alternans and baseline patient characteristics
Study Population Sample Size Men (%) Age
(Mean ± SD, 
years)
LVEF
(mean ± SD, %)
Follow-Up 
(mean ± SD, 
months)
Quality Score*
Chow 2006 [18] ICM 768 84 67 27 18 ± 10 good
Bloomfield 2006 
[6]
DCM 549 71 56 ± 10 25 ± 6 20 ± 6 good
Grimm 2003 [19] ICD and LV > 56 
mm
263 73 48 ± 12 30 ± 10 52 ± 21 good
Klingenheben 
2000 [22]
CHF 107 80 56 ± 10 28 ± 7 15 good
Ikeda 2000 [20] Post-MI 102 83 60 ± 9 NR 13 ± 6 moderate
Kitamura 2002 
[21]
DCM 83† 81 52 ± 15 NR 21 ± 14 moderate
Sarzi Braga 2004 
[24]
CHF 44† 89 59 ± 9 29 ± 7 19 ± 11 moderate
Sakabe 2001 [23] DCM 30† 91 53 ± 16 33 ± 15 13 ± 11 moderate
Abbreviations: CHF: congestive heart failure; DCM: dilated cardiomyopathy; ICM: ischemic cardiomyopathy; ICD: implantable cardioverter 
defibrillator; LV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; MI: myocardial infarction; NR: not reported.
* Quality was assessed using an 7-item quality assessment score [see Additional file 1]. Good quality was defined as a score of 6–7, moderate quality 
was defined as a score of 4–5, and poor quality was defined as a score of 1–3.
† The sample sizes reported in the table represent the number of patients included in the analyses. A number of studies enrolled patients who were 
subsequently excluded from the analyses. The other numbers are based on the number of patients enrolled. These studies include Kitamura (104 
patients enrolled)[21], Sarzi Braga (46 patients enrolled) [24], and Sakabe (34 patients enrolled)[23].BMC Cardiovascular Disorders 2009, 9:5 http://www.biomedcentral.com/1471-2261/9/5
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Discussion
This systematic review and meta-analysis examined
MTWA as a predictor of mortality and severe arrhythmic
events for primary prevention in patients with left-ven-
tricular dysfunction. We were unable to identify any rand-
omized trials investigating this diagnostic modality.
Consequently, our conclusions are based on less rigorous
cohort studies, which are further weakened by a lack of
standardization. Nevertheless, a positive MTWA test result
cumulatively predicted an increased risk of mortality and
severe arrhythmic events compared with a negative test.
MTWA may therefore possess some clinical utility as a
stratification tool to assess short- to moderate-term risk in
high-risk primary prevention populations. This is impor-
tant as the majority of the economic burden associated
with the prevention of arrhythmic events by ICD implan-
tation occurs in this population [25,26]. However, the
wide credible interval suggests the clinical utility may
range from very modest to substantial and highlights the
need for additional high-quality studies to better refine
these estimates. Furthermore, our review identified a
dearth of data examining the utility of MTWA for long-
term risk stratification; only 1 study to date has examined
the ability of MTWA to predict events after 2 years of fol-
low-up.
MTWA as a predictor of cardiac events has been examined
in several non-systematic, narrative reviews [7,8,27-31]
and one systematic review. This systematic review
included a meta-analysis and also concluded that MTWA
predicted an increased risk of mortality and arrhythmic
events [32]. Compared to the previous meta-analysis [32],
which included more heterogeneous studies, we have
avoided duplicate publications, added several more recent
publications, and included only patient populations with
significant left ventricular dysfunction. Our study is there-
fore more homogenous and specifically addresses the util-
ity of MTWA in high-risk primary prevention. In addition,
we have concentrated on comparing ratios of predictive
values and avoided summarizing predictive values as
these results are heavily dependent on study disease prev-
alence and follow-up time. Despite these important differ-
ences, the results of this previous study [32] are generally
consistent with those of the present meta-analysis.
The utility of MTWA for predicting severe arrhythmic
events in patients with left ventricular dysfunction also
has been examined in 3 trials that have been recently pre-
sented at scientific meetings but not included in this meta-
analysis. In the MASTER-I trial, which was presented at the
Late Breaking Clinical Trial Session of the American Heart
Association 2007 Scientific Sessions, 575 post-MI patients
with left ventricular ejection fractions ≤ 30% and no his-
tory of severe arrhythmic events from 50 U.S. hospitals
were followed for at least 2 years [33]. All patients received
an ICD. The primary endpoint of the MASTER I trial was
life-threatening ventricular tachyarrhythmic event,
defined as either arrhythmic death or appropriate ICD dis-
Table 2: Test characteristics of microvolt T-wave alternans as a predictor of mortality or severe arrhythmias
Patients with Endpoint (n/N) Non-negative vs Negative MTWA†
Study Endpoint* Positive
MTWA
Negative
MTWA
Indeterminate MTWA Sensitivity Specificity PPV NPV
Chow 2006 [18] ACM 78/514†† 21/254 NR 87.6 34.8 15.2 91.7
AD 33/514†† 9/254 NR 78.6 33.7 6.4 96.5
Bloomfield 2006 [6] ACM/SA/ICDS 47/360†† 4/189 NR 92.2 37.1 13.1 97.9
Grimm 2003 [19] CD/SA 18/137 7/72 13/54 82.6 28.9 16.2 90.3
Klingenheben 2000 [22] CD/VT/VF 11/52 0/33 2/22 100 35.1 17.6 100
Ikeda 2000 [20] SA 14/50 1/52 NR NE NE NE 98.1
Kitamura 2002 [21] CD 3/46 0/37 NR NE NE NE 100
SA 8/46 1/37 NR NE NE NE 97.2
CD/SA 11/46 1/37 NR NE NE NE 97.2
Sarzi Braga 2004 [24] CD 7/23 0/13 0/8 100 35.1 22.6 100
Sakabe 2001 [23] SA 13/24 0/6 NR NE NE NE 100
Abbreviations: ACM: all-cause mortality; AD: arrhythmic death; CA: cardiac arrest; CD: cardiac death; ICDS: implantable cardioverter defibrillator 
shock; NPV: negative predictive value; NE: not estimable; NR: not reported; PPV: positive predictive value; SA: severe arrhythmias (ventricular 
fibrillation or ventricular tachycardia); VF: ventricular fibrillation; VT: ventricular tachycardia;
* The inclusion of more than one clinical endpoint per row represents the use of a composite endpoint.
† Test characteristics are for non-negative (i.e., positive and indeterminate) vs negative MTWA. Valid estimates of the sensitivity, specificity, and 
PPV can only be obtained when indeterminate tests are included. Consequently, test characteristics for Grimm [19], Klingenheben [22], and Sarzi 
Braga [24] were recalculated using non-negative or negative MTWA. Sensitivity, specificity, and PPV for studies that excluded indeterminate tests 
were not estimable (NE).
†† The studies conducted by Chow [18] and Bloomfield [6] categorized participants as non-negative or negative MTWA. Consequently, these data 
represent patients with endpoints who had a non-negative test.BMC Cardiovascular Disorders 2009, 9:5 http://www.biomedcentral.com/1471-2261/9/5
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charge, and the secondary endpoints were total and cause-
specific mortality. Non-negative MTWA did not appear to
predict life-threatening ventricular tachyarrhythmias
(hazard ratio (HR): 1.26, 95% confidence interval (CI):
0.76, 2.09), although with a wide 95% CI, we are unable
to rule out a clinical difference of the same magnitude as
that reported in the current meta-analysis. The MASTER I
investigators did find an increase in all-cause mortality
among patients with non-negative MTWA (HR: 2.04,
95%CI: 1.10, 3.78). In the MASTER II trial, the utility of
MTWA was examined in 303 patients with moderate ven-
tricular dysfunction (i.e., left ventricular ejection fraction
between 31% and 40%), 48% of whom received an ICD
[34]. The MASTER II trial, which excluded patients with
indeterminate test results, provided inconclusive results
due to a lower event rate than expected (positive MTWA vs
negative MTWA: unadjusted stratified HR: 1.22, 95% CI:
0.34, 4.39; adjusted stratified HR: 1.20, 95% CI = 0.33,
4.31). In the ABCD trial, Costantini and colleagues exam-
ined the utility of MTWA and electrophysiological testing
to predict different arrhythmic outcomes [35]. This study
involved 566 patients with ischemic cardiomyopathy, an
ejection fraction < 40%, and documented non-sustained
VT, and patients were followed for 2 years. The investiga-
tors found that, at 1 year, non-negative MTWA was an
important predictor of polymorphic VT, VF, and SCD
(2.7% vs 0%, p = 0.04) but not of monomorphic VT (data
not provided). At 2 years, non-negative MTWA was not
associated with either outcome.
Forest plot of the risk of mortality or severe arrhythmias among those with a positive microvolt T-wave alternans test com- pared with those with a negative microvolt T-wave alternans test Figure 2
Forest plot of the risk of mortality or severe arrhythmias among those with a positive microvolt T-wave alter-
nans test compared with those with a negative microvolt T-wave alternans test.BMC Cardiovascular Disorders 2009, 9:5 http://www.biomedcentral.com/1471-2261/9/5
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Although these studies provide important information
regarding the utility of MTWA, we have not included them
in our meta-analysis for a number of reasons. First, they
have not yet undergone the rigorous peer-review associ-
ated with publication of a full manuscript. Second, in the
MASTER-I trial, all patients received an ICD regardless of
MTWA test. This trial therefore examines an inherently
different question than the one posed in our meta-analy-
sis. Finally, only limited information is available for each
study, rending it difficult to assess the eligibility of each
study relative to the inclusion/exclusion criteria of our
meta-analysis. This limited information available also
prevents the inclusion of these data in the analyses, partic-
ularly in the case of the ABCD trial. Despite these limita-
tions, it is unlikely that the inclusion of these results
would alter the conclusions drawn in the present study,
particularly given the consistency of the point estimates
obtained in these studies with our results.
Our study has a number of strengths. This is the first sys-
tematic review and meta-analysis that focuses on the use
of MTWA in the setting of primary prevention in patients
with left-ventricular dysfunction. By excluding studies of
healthy individuals, we provide a more valid measure of
MTWA specificity and negative predictive value as it per-
tains to clinical practice. Second, our meta-analysis
included patients with indeterminate test results, avoiding
a potentially important selection bias. Third, our system-
atic review and meta-analysis was conducted using a pre-
specified protocol and in accordance with the MOOSE cri-
teria [14]. Finally, this is the first meta-analysis to com-
pare the different MTWA categories (i.e., positive vs
negative, positive vs indeterminate, negative vs indetermi-
Forest plot of the risk of mortality or severe arrhythmias among those with a non-negative microvolt T-wave alternans test  compared with those with a negative microvolt T-wave alternans test Figure 3
Forest plot of the risk of mortality or severe arrhythmias among those with a non-negative microvolt T-wave 
alternans test compared with those with a negative microvolt T-wave alternans test.BMC Cardiovascular Disorders 2009, 9:5 http://www.biomedcentral.com/1471-2261/9/5
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nate), rather than simply grouping test results as negative
and non-negative. Furthermore, our comparison of nega-
tive and non-negative MTWA was restricted to studies that
reported indeterminate tests results, resulting in a more
valid estimate of the effect of MTWA.
Our meta-analysis also has some potential limitations.
First, we restricted our search to full-text studies published
in English and thus may be affected by language and/or
publication bias. Although our decision to not include
studies recently published as abstracts may affect the pre-
cision of our estimates, it is unlikely to bias our results.
These 3 studies have not been published because they are
recently completed; the publication status is not due to
the positive or negative nature of their results. Second,
despite recommendations from the manufacturer strongly
encouraging retesting following an indeterminate result
[36], none of the studies identified in our systematic
review conducted retesting. Retesting could decrease the
number of patients with indeterminate test results and
could potentially alter the sensitivity and specificity of
MTWA. Thus, we may possibly be underestimating the
potential benefits of MTWA testing. Third, there was some
heterogeneity present in the individual studies included
in our systematic review and meta-analysis. Studies varied
in patient characteristics, duration of follow-up, study
endpoints, and distribution of MTWA categories. Hetero-
geneity was also present in test classification, with some
studies grouping patients into 3 categories (positive, neg-
ative, and indeterminate), some grouping patients into
negative and non-negative, and the remaining studies
excluding indeterminate tests. However, our results,
although inconclusive due to wide CrIs that include both
no effect and clinical important differences, suggest that
there is no difference in risk of mortality or severe arrhyth-
mic events between patients with positive MTWA and
those with indeterminate results. Consequently, grouping
patients as negative and non-negative is likely a valid
approach. Fourth, some studies excluded indeterminate
tests when calculating sensitivities and specificities. Where
possible, we re-calculated the sensitivity, specificity, and
positive and negative predictive values comparing non-
negative and negative MTWA. However, we were unable
to re-calculate these test characteristics for all studies. We
also examined MTWA using the ratio of positive predictive
values, which is not affected by the underlying disease
prevalence. Fifth, we were limited to aggregate data and
thus were unable to compare the predictive ability of
MTWA to those of other tests, including New York Heart
Association Class and left ventricular ejection fraction.
Sixth, the ability of MTWA to predict events occurring 2 or
more years after testing remains unclear. Finally, all stud-
ies included in our meta-analysis were observational stud-
ies. The potential effects of selection bias and
confounding must be considered when interpreting their
results.
Conclusion
Although the body of evidence is far from ideal, MTWA
appears to predict mortality and severe arrhythmias occur-
ring within one to two years in patients with left-ventricu-
lar dysfunction and no previous history of ventricular
arrhythmias. Patients with positive or indeterminate tests
are at higher risk of mortality and severe arrhythmic
events than patients with negative MTWA, potentially aid-
ing the identification of patients most likely to benefit
from prophylactic ICD implantation and thereby perhaps
improving the cost-effectiveness of this therapy. There
remains a need to examine MTWA in well-conducted ran-
domized controlled trials as well as the ability of MTWA
to predict long-term outcomes. While awaiting further
quality studies, physicians and policy makers may wish to
consider MTWA to help identify patients in the greatest
need of aggressive primary prevention and ICD implanta-
tion.
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